J.P. Morgan Healthcare Conference. January 15, 2009
|
|
- Florence Gwenda Bryant
- 5 years ago
- Views:
Transcription
1 J.P. Morgan Healthcare Conference January 15, 2009
2 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet s actual results could differ materially from those, express or implied, in this presentation. The forward-looking statements include our expectations regarding our operating and financial results and the clinical development of potential products. Various factors may cause differences between our expectations and actual results including: competition from alternative therapies; disappointing results from clinical trials; and failure to obtain regulatory approval for potential products. Other risk factors we face are discussed in the Risk Factors sections of each of our SEC filings, which may be obtained at the Investors section of our website at We expressly disclaim any obligation or undertaking to updates or revise any forward-looking statements to reflect any change in expectations, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement. Copyright Notice All of the content in this presentation is copyrighted and may not be reproduced, distributed or revised in any manner without the prior written consent of Facet Biotech. Any use without consent may violate copyright law and other laws or regulations. Copyright 2009, Facet Biotech Corporation. All Rights Reserved. 2
3 Facet Biotech: unique opportunity Promising pipeline Compelling biology Solid financial position Strategic collaborations Core capabilities 3
4 Facet Biotech: planning for success Opportunity to shape Facet Biotech into a new and exciting company Narrow focus Establish diversified and risk-balanced pipeline Leverage antibody expertise Extend financial runway Assess and enhance organizational capabilities Strategic business review completed in January
5 Facet Biotech: foundation for a new company Narrow focus and enhance depth of expertise Pursue a single therapeutic area oncology Focus research efforts on a validated biology approach Capitalize on and expand internal and external expertise in oncology Augment pipeline in a focused, disciplined manner Focus business development opportunities in oncology P1/2 clinical-stage assets with validated biology a priority Deliver value within a four-year period Progress programs to P2 proof of concept Evaluate opportunities for protein engineering technology platform Increase financial stability and flexibility Of critical importance in this capital-constrained environment 5
6 Facet Biotech: financial strength Ability to fund operations for ~4 years Based on over $400 million in initial capitalization and financial projections Includes in-licensing 2009 cash utilization of ~$110 million Includes ~$10 million in one-time, workforce-related costs Excludes receipt of potential milestones, including a $15 million opt-in for PDL241 Does not assume facility sub-lease Does not reflect costs related to in-licensing opportunities Workforce of ~200 positions Reflective of recently announced reduction of 80 positions 6
7 Facet Biotech: pipeline overview Preclinical Phase 1 Phase 2 daclizumab multiple sclerosis* volociximab elotuzumab PDL192 ovarian* lung* multiple myeloma (monotherapy)** multiple myeloma (combination)** solid tumors PDL241 immunologic diseases*** *in collaboration with Biogen Idec **in collaboration with Bristol-Myers Squibb (BMS) ***BMS has option to include in collaboration oncology immunology 7
8 Daclizumab: demonstrated proof of concept in MS CHOICE primary endpoint adjusted new or enlarged Gd+ lesions Adjusted Means of New/Enlarged Gd+ Lesions % reduction* 95% CI: -68%, +76% P= % reduction* 95% CI: -88%, -34% P= IFN/Placebo IFN/DAC 1 mg/kg IFN/DAC 2 mg/kg *P-values, percent reductions, and 95% confidence intervals were estimated from a negative binomial regression adjusting for the number of baseline lesions and type of MS (RRMS vs. SPMS). Data presented by M. Kaufman; AAN Anti-IL-2 humanized mab First approved humanized mab P2 CHOICE MS trial met primary endpoint Secondary endpoint of annualized relapse rate Reduction of 32% low dose and 43% high dose compared to placebo (unadjusted) In collaboration with Biogen Idec 8
9 Daclizumab: SELECT trial Screening Follow-up Period (No Dac) Randomize MRI: Week weeks 24 weeks 24 weeks 297 subjects 1:1:1 300mg q 4 wks 150mg q 4 wks Placebo q 4 wks 300mg q 4 wks 150mg q 4 wks Placebo q 4 wks- If a relapse is confirmed then IFN is acceptable concomitant medication Led by Biogen Idec, study progressing well; anticipate running through 2009 Continued unmet need for MS and need for new treatments Prevalence* (2005): 524,700 cases (U.S., EU, Japan) * Market research data 9
10 Volociximab: unique anti-angiogenic agent Anti-alpha5-beta1 integrin mab a novel angiogenesis pathway Discovered and developed in-house P1 and P1/2 studies ongoing in ovarian and NSCLC In collaboration with Biogen Idec 10
11 Elotuzumab: novel anti-cs1 antibody Elotuzumab enhances bortezomib-mediated anti-tumor activity in an OPM2 model* Tumor Volume (mm 3 ) Study Day Elotuzumab Dose Days Bortezomib Dose Days Control Ab & PBS Elotuzumab & PBS Control Ab & Bortezomib Elotuzumab & Bortezomib Humanized antibody to CS1 Proven target expression in preclinical studies Three P1 trials underway In collaboration with Bristol-Myers Squibb * Data presented at ASH Elotuzumab was used at a suboptimal dose; bortezomib was used at the optimal dose. 11
12 PDL192: anti-tweak* receptor antibody Novel, humanized mab to the Tweak receptor, expressed in solid tumors Preclinical data presented at the EORTC meeting in October P1 study ongoing; potential in multiple tumor types Unpartnered program; worldwide rights maintained PDL192 has two proposed mechanisms of action: Directly inhibits the growth of some TWEAK-R-expressing tumor cells Recruits immune effector cells to kill tumor cells via antibody-dependent cellular cytotoxicity (ADCC) * TWEAK: tumor necrosis factor-like weak inducer of apoptosis 12
13 Facet Biotech: key collaborations Collaboration Products Cost and Profitsharing Development and Regulatory Milestones Sales-based Milestones Elotuzumab Option for PDL241 Shared global development costs: BMS 80% and PDL 20% U.S. profit split: greater portion of profits to PDL than represented by cost sharing percentage Elotuzumab: up to $480 million PDL241: $15 million if BMS opts in at completion of set preclinical studies Up to $230 million Elotuzumab: up to $200 million PDL241 (if BMS opts in): up to $200 million Daclizumab in MS Volociximab in all indications 50/50 co-development and cocommercialization Daclizumab: up to $250 million Volociximab: up to $300 million Volociximab: up to $100 million 13
14 Facet Biotech: portfolio management Maximize portfolio returns Evaluate each asset as an investment Applicable to both existing and prospective assets Establish a diversified and risk-balanced portfolio Important given inherent nature of biotech industry Focus on beating the odds Focused strategy Deep biological insight Pursue external assets with biological validation Disciplined diligence and financial modeling processes 14
15 Facet Biotech: value drivers for the next 12 months DAC MS (SELECT) P2 initiated Elotuzumab + Velcade P1 initiated 2009 financial outlook DAC MS (SELECT) P2 update Elotuzumab P1 results (3 trials) Elotuzumab + Revlimid P1 initiated BMS option on PDL241 M200 P1 NSCLC initiated PDL192 IND filed PDL192 P1 initiated M200 P1 NSCLC and ovarian results PDL192 P1 safety data
16 Facet Biotech: investment rationale Promising pipeline led by daclizumab P2 program in MS Early-stage programs focused in oncology Strong research based on validated biology Pursue candidates that are 12 months pre-ind Core platform technology in antibody engineering Solid financial position Well-capitalized with over $400 million Able to fund business operations for ~4 years 2009 cash utilization expected to be ~$110 million Strategic collaborations mitigate risk and provide significant milestone opportunities Explore new opportunities to augment existing pipeline Core capabilities Build a culture of innovation, performance and discipline 16
Corporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationCorporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER March 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements
More informationGood morning and thank you for joining us for our quarterly update.
Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have
More informationClinical-Stage Pipeline Today
Our Targeted Antibody Payload (TAP) technology uses tumor-targeting antibodies to deliver one of our potent cancer-cell killing agents specifically to tumor cells. Multiple TAP compounds are in clinical
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
FOR IMMEDIATE RELEASE December 21, 2017 Eisai Co., Ltd. Biogen Inc. ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationuniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington,
More informationGlobalization and Innovation will drive growth
JPMorgan Healthcare Conference The New Takeda January 10, 2012 Yasuchika Hasegawa President & CEO 0 Globalization and will drive growth Leading worldwide pharmaceutical company operating in 70 countries
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More information31st Annual J.P. Morgan Healthcare Conference
31st Annual J.P. Morgan Healthcare Conference Achieving Sustainable Growth January 8, 2013 Yasuchika Hasegawa President & CEO 1 Forward-Looking Statements This presentation contains forward-looking statements
More informationJefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
More informationRoche Committed to Innovation. Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008
Roche Committed to Innovation Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 This presentation contains certain forward-looking statements. These forward-looking statements
More informationFor personal use only
Antisense Therapeutics Ltd AGM Presentation and Questions on notice November, 2016 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationMultiple myeloma Forecast DMKC Published on 07/04/2016
Multiple myeloma Forecast DMKC0157485 Published on 07/04/2016 Datamonitor Healthcare forecasts that the extended indications for these drugs will lead to considerable uptake across the treatment algorithm,
More informationProsensa Therapeutics R&D in ultra-rare disease
Prosensa Therapeutics R&D in ultra-rare disease European Business Development Conference Dusseldorf, September 24, 2013 Tina C Flatau VP Alliances and Project Management Forward-Looking Statements This
More informationFourth Quarter and Full Year 2017 Financial Results. February 21, 2018
Fourth Quarter and Full Year 2017 Financial Results February 21, 2018 Agenda Introduction Sarah Carmody, Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES
ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular
More informationREGENXBIO Inc. Ticker: RGNX
REGENXBIO Inc. Ticker: RGNX I know what you are thinking. You are about to read another biotech report with more acronyms than words you know the definitions. I promise you this report is written in layman
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationForward-looking statements
March 2017 Forward-looking statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors described under
More informationInnovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future
Innovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future Donald Olds Chief Operating Officer & CFO Aegera Therapeutics Inc. June 8, 2010 1 Discussion Points Why do biotech
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationUnique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd
Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations [mabs -monoclonal antibodies ] Peter Lloyd Head of Pharmacokinetics-Pharmacodynamics Novartis Biologics
More informationOPT-302: a VEGF-C/VEGF-D Trap for wet AMD
OPT-302: a VEGF-C/VEGF-D Trap for wet AMD Ophthalmology Innovation Summit, Nov 12 2015 Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin PhD, CEO & MD megan.baldwin@opthea.com 2 Disclaimer Investment
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationWorking together for better health. Partnering with Boehringer Ingelheim
Working together for better health Partnering with Boehringer Ingelheim Welcome to Boehringer Ingelheim Partnering Our vision Value through innovation is a reality A demonstrable history of innovation
More informationCRITERIA FOR PROJECT SELECTION
CRITERIA FOR PROJECT SELECTION The CITN is a network of eperienced immunotherapy investigators with inherently diverse research interests. Thus, we have established guidelines to epedite project selection
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationIntec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017
Intec Pharma Unfolding drug delivery solutions Investor Presentation Nasdaq: NTEC June 2017 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as we or our ) contains forward-looking
More informationJ.P. Morgan Healthcare Conference BILL CHASE BILL CHASE EXECUTIVE VP, FINANCE & CFO
J.P. Morgan Healthcare Conference BILL CHASE BILL CHASE EXECUTIVE VP, FINANCE & CFO Disclaimer and Forward Looking Statement This presentation and its contents are confidential and may not be reproduced,
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationThe Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma
Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 1, August 13, 2015 Antibodies: The Body s Foot Soldiers in the Battle Against Disease Speakers Moderator: Joseph Mikhael,
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationCellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016 Cellular Tumor
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPfizer To Acquire Hospira
For immediate release: February 5, 2015 Media Contact: Joan Campion (212) 733-2798 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer To Acquire Hospira - Transaction will significantly enhance Pfizer
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationSamatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination
More informationInventiva: acceleration of the clinical development activities and consolidation PRESS RELEASE of the financial position in 2016
COMMUNIQUE DE PRESSE Inventiva: acceleration of the clinical development activities and consolidation PRESS RELEASE of the financial position in 2016 Launch of IVA337 Phase IIb trial in NASH Initiation
More informationBiotest AG. Jefferies Healthcare Conference New York, June 7-10, 2016
. Jefferies Healthcare Conference New York, June 7-10, 2016 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial
More informationAbGn-107, an ADC Targets Gastrointestinal Tumors
AbGn-107, an ADC Targets Gastrointestinal Tumors For a Healthier Life Presented by Ron Lin Feb. 22, 2016 All Rights reserved AbGenomics International Inc. 4966 El Camino Real, Suite 200, Los Altos, CA
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders March 2018 Mar-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationCorporate Presentation. Roberto Bellini President and Chief Executive Officer
Corporate Presentation Roberto Bellini President and Chief Executive Officer September 2012 Forward Looking Statement Certain statements contained in this presentation, other than statements of fact that
More informationGoldman Sachs Health Care Conference
Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations Safe Harbor Statement This presentation contains forward-looking
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationImmunotherapy in Hemato-Oncology
ESMO Preceptorship Programme Immuno-Oncology From tumor immunology to clinical application 2-3 November 2016 Zurich - CH Immunotherapy in Hemato-Oncology Markus G. Manz Klinikdirektor Hämatologie USZ Leiter
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationThe tetravalent bispecific NK-cell engaging antibody AFM13 (CD30/CD16A) engages and primes innate immune cells for anti-cancer immunity
The tetravalent bispecific NK-cell engaging antibody AFM13 (CD30/CD16A) engages and primes innate immune cells for anti-cancer immunity Martin Treder, PhD Affimed GmbH AACR Annual Meeting 2017 Forward-looking
More informationAMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS (CARFILZOMIB) FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
January 29, 2015 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS Amgen (NASDAQ:AMGN) and its subsidiary Onyx
More informationDEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS DEUTSCHE BANK 42ND ANNUAL HEALTH CARE CONFERENCE MAY 4, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationASIT BIOTECH ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS AND EURONEXT PARIS
This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for securities. This announcement is not a prospectus
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationRegulatory Perspective
Regulatory Perspective Presented by Dr Maria Isaac MASc, MD, PhD, Pharmaceutical Medicine Physician, Psychiatrist Senior Scientific Officer An agency of the European Union Disclaimer The views expressed
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationPfizer Program in DMD. Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017
Pfizer Program in DMD Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017 Myostatin Inhibitor for the Potential Treatment of Duchenne Muscular Dystrophy Disclaimer This presentation includes
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationProsensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy
Prosensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy Leiden, The Netherlands, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V.
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationTITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE
TITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE JULY 23, 2014 Forward-Looking Statements This presentation contains forward-looking statements, including statements about
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationFINANCIAL PERSPECTIVES
FINANCIAL PERSPECTIVES M³ - Meet Merck Management Marcus Kuhnert, CFO Darmstadt December 10, 2015 Disclaimer Cautionary Note Regarding Forward-Looking Statements This communication may include forward-looking
More information